Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 13/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25968787 | 0.90 | TRPA1 (0.52) | TRPA1MAPTHTTSMN1; SMN2NPSR1 | |
| SCHEMBL25968853 | 0.89 | TRPA1 (0.51) | TRPA1P2RX3 | |
| SCHEMBL25970104 | 0.87 | TRPA1 (0.49) | TRPA1P2RX3 | |
| SCHEMBL25968928 | 0.84 | TRPA1 (0.56) | TRPA1MAPTHTTSMN1; SMN2NPSR1 | |
| SCHEMBL25968929 | 0.84 | TRPA1 (0.56) | TRPA1HTTSMN1; SMN2 | |
| SCHEMBL25968920 | 0.83 | TRPA1 (0.52) | TRPA1 | |
| SCHEMBL25968925 | 0.82 | TRPA1 (0.54) | TRPA1 | |
| SCHEMBL31524009 | 0.82 | TRPA1 (0.52) | TRPA1 | |
| SCHEMBL25968786 | 0.82 | TRPA1 (0.52) | TRPA1 | |
| SCHEMBL25968783 | 0.82 | TRPA1 (0.52) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154139-A1 | PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS | D. E. SHAW RESEARCH, LLC | 2025-05-15 | — | — | US | disclosed |
| WO-2023150591-A2 | PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS | D.E. SHAW RESEARCH, LLC (US) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154139-A1 | PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS | TRPA1, TRPV1, TRPV5 | TRPA1 1/4885CYP1A1 407/4885HPGD 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.